Merck KGaA Strengthens Anticancer Pipeline With Novel EGFR-Targeted Antibody Combination
This article was originally published in The Pink Sheet Daily
Executive Summary
A mixture of two antibodies that may have a novel synergistic effect against EGFR-expressing tumors has been licensed to Merck KGaA for development worldwide by Denmark's Symphogen, the recipient back in 2011 of one of the largest ever VC-backed financing rounds in Europe.
You may also be interested in...
Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge
AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.
Threshold Presses On In Two Phase III Cancer Trials As Competitors Wilt
Threshold and partner Merck Serono are benefiting from recent high-profile failures in sarcoma and pancreatic cancer. Armed with $100 million in payments since signing with Merck in February 2012, Threshold needs to rise above stiff odds and what some view as equivocal Phase II pancreatic cancer results.
Can Erbitux Make Inroads In First-line Colon Cancer With Approved Companion Dx In Tow?
Erbitux wins FDA approval for first-line metastatic colorectal cancer negative for KRAS mutations detected with a companion diagnostic specifically approved for the drug. In theory, earlier use could help shore up sales. But the drug faces a tough competitor in the dominant Avastin and new products are on the near horizon.